Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00488618 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 238
- Enrollment target
NCT00488618 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 238 participants.
The verdict
NCT00488618, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 238 participants
- Enrollment target
Study Summary
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania. This study will be 5 weeks in duration; 3 weeks double-blind treatment and 2-weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of two treatment groups: RGH-188 or placebo
Interventions
- DRUG Placebo
- DRUG Cariprazine (RGH-188)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00488618
The ClinicalTrials.gov registry entry for NCT00488618 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00488618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00488618 about?
NCT00488618 is a clinical study titled "Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania". This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania. This study will be 5 weeks in duration; 3 weeks double-blind treatment and 2-weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to...
What is the current status of trial NCT00488618?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 238 participants. The study started on 2007-06. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00488618?
The interventions under investigation include: Placebo (DRUG), Cariprazine (RGH-188) (DRUG).
Who is sponsoring clinical trial NCT00488618?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.